iota Biosciences is a wholly-owned subsidiary of Astellas Pharma developing implantable bioelectronic devices for therapeutic and diagnostic use. The tech stack reveals a hardware-first company: embedded systems (C/C++, VHDL, SystemVerilog, RTOS, Embedded Linux) paired with wireless connectivity (Bluetooth Low Energy, WiFi, Zigbee) and power optimization tools (LTspice, PSpice). The hiring mix is engineering-heavy with senior and manager-level roles dominating, reflecting both the complexity of Class III device development and the resource constraints noted across pain-point data—the company is simultaneously executing early feasibility studies, pivotal trials, design transfer, and manufacturing scale-up while establishing quality systems.
iota Biosciences, founded in 2017 and based in Alameda, California, builds implantable bioelectronic devices derived from ultrasound technology developed at UC Berkeley. The company operates as a subsidiary of Astellas Pharma US, a global pharmaceutical company, providing access to regulatory expertise and market reach. With 51–200 employees, iota is in the critical early-to-mid stage of medical device development: executing feasibility and pivotal studies, implementing ISO 14971 risk management, designing next-generation Class III active implantable devices, and scaling manufacturing processes. The product roadmap spans diagnostic and therapeutic applications across nerve interfaces and implantable platforms.
Early feasibility studies, pivotal trials, next-generation Class III implantable devices, design transfer and manufacturing scale-up, big data infrastructure for embedded processor data, and DevOps improvements.
Embedded systems (C/C++, VHDL, SystemVerilog, RTOS, Embedded Linux), wireless (Bluetooth Low Energy, WiFi, Zigbee), power simulation (LTspice, PSpice), hardware design (Altium, Allegro, KiCad), MATLAB, React/TypeScript/Node.js frontend, AWS, and HL7 FHIR for medical data.
Other companies in the same industry, closest in size